Do Diabetic Foot Infections With Methicillin-Resistant Staphylococcus aureus Differ From Those With Other Pathogens?

被引:53
|
作者
Zenelaj, Besa [1 ,2 ]
Bouvet, Cindy [1 ,2 ]
Lipsky, Benjamin A. [1 ,2 ,3 ]
Uckay, Ilker [1 ,2 ]
机构
[1] Univ Hosp Geneva, CH-1211 Geneva 14, Switzerland
[2] Fac Med, Geneva, Switzerland
[3] Univ Oxford, Oxford, England
来源
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS | 2014年 / 13卷 / 04期
关键词
diabetic foot infection; Staphylococcus aureus; MRSA; review; treatment; RISK-FACTORS; SOFT-TISSUE; MICROBIAL PROFILE; CLINICAL-OUTCOMES; TREATMENT FAILURE; COMPLICATED SKIN; ULCERS; VANCOMYCIN; OSTEOMYELITIS; PREVALENCE;
D O I
10.1177/1534734614550311
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
There is controversy as to whether or not diabetic foot infections (DFIs) caused by methicillin-resistant Staphylococcus aureus (MRSA) are associated with worse outcomes than DFIs caused by other pathogens. To address this issue we performed a nonsystematic literature search of published articles in English language journals seeking studies reporting on the outcomes of DFIs related to their microbiology. We retrieved 48 articles published from 1999 to 2013 that described a total of 7771 cases of DFI. The overall proportion of DFIs with an isolate of S aureus was about 30%; just over one third of these (11% of all cases) were MRSA strains. Among the DFI cases caused by MRSA 1543 were episodes of soft tissue infections and 113 of osteomyelitis, while non-MRSA organisms caused 5761 soft tissue infections and 354 cases of osteomyelitis. Only 5 of the included articles attempted a comparison between DFI caused by MRSA and those caused by other pathogens, with no clear differences noted. The median total duration of antibiotic therapy for DFI caused by MRSA was 26 days, of which a median of 10 days was given intravenously. Only a few articles reported the proportion of patients with a recurrence, but they often did not differentiate between MRSA and non-MRSA cases. Four publications reported a worse functional or microbiological outcome in MRSA, compared to non-MRSA, cases, but the findings were variable and differences did not seem to be significant. Many trials failed to adjust for case-mix or to definitively demonstrate a relationship between microbiology and outcomes. Few of the articles specifically commented on whether the MRSA isolates were health care- or community-acquired strains. Notwithstanding the substantial limitations of the available literature, there does not appear to be a need for any special treatment for DFI caused by MRSA. The current guidelines for treating according to established international recommendations seem appropriate.
引用
收藏
页码:263 / 272
页数:10
相关论文
共 50 条
  • [21] Methicillin-resistant Staphylococcus aureus:: an increasing problem in a diabetic foot clinic
    Tentolouris, N
    Jude, EB
    Smirnof, I
    Knowles, EA
    Boulton, AJM
    DIABETIC MEDICINE, 1999, 16 (09) : 767 - 771
  • [22] Methicillin-resistant Staphylococcus aureus nasal carriage and infection among patients with diabetic foot ulcer
    Lin, Shin-Yi
    Lin, Nai-Yu
    Huang, Yu-Yao
    Hsieh, Chi-Chun
    Huang, Yhu-Chering
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2020, 53 (02) : 292 - 299
  • [23] Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening: Clinical Use for Excluding Diabetic Foot Infection with MRSA
    Sfeir, Maroun M.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (07)
  • [24] Telavancin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections
    Rodvold, Keith A.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 : S35 - S37
  • [25] Methicillin-Resistant and -Susceptible Staphylococcus aureus Infections in Dogs
    Faires, Meredith C.
    Traverse, Michelle
    Tater, Kathy C.
    Pearl, David L.
    Weese, J. Scott
    EMERGING INFECTIOUS DISEASES, 2010, 16 (01) : 69 - 75
  • [26] Utility of Methicillin-Resistant Staphylococcus aureus Nares Screening for Patients with a Diabetic Foot Infection
    Mergenhagen, Kari A.
    Croix, Michael
    Starr, Kaitlyn E.
    Sellick, John A.
    Lesse, Alan J.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (04)
  • [27] Revisiting Methicillin-Resistant Staphylococcus aureus Infections
    Waness, Abdelkarim
    JOURNAL OF GLOBAL INFECTIOUS DISEASES, 2010, 2 (01) : 49 - 56
  • [28] Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infection in India: A Growing Menace
    Viswanathan, Vijay
    Pendsey, Sharad
    Radhakrishnan, Chandni
    Rege, Tushar Devidas
    Ahdal, Jaishid
    Jain, Rishi
    INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS, 2019, 18 (03): : 236 - 246
  • [29] Community-Associated Methicillin-Resistant Staphylococcus aureus Infections in Israel
    Nevet, Alon
    Ashkenazi, Shai
    Samra, Zmira
    Livni, Gilat
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2010, 12 (07): : 428 - 430
  • [30] Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections
    Harting, Julie
    Fernandez, Francisco
    Kelley, Rob
    Wiemken, Tim
    Peyrani, Paula
    Ramirez, Julio
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017, 89 (04) : 294 - 299